POINT Biopharma Global (POINT Biopharma Global) Beneish M-Score : 0.00 (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for POINT Biopharma Global's Beneish M-Score or its related term are showing as below:

During the past 3 years, the highest Beneish M-Score of POINT Biopharma Global was 0.00. The lowest was 0.00. And the median was 0.00.

POINT Biopharma Global Beneish M-Score Historical Data

The historical data trend for POINT Biopharma Global's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Beneish M-Score Chart

POINT Biopharma Global Annual Data

Trend

Dec20

Dec21

Dec22

Beneish M-Score

POINT Biopharma Global Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Beneish M-Score	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of POINT Biopharma Global's Beneish M-Score

For the Biotechnology subindustry, POINT Biopharma Global's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

POINT Biopharma Global's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Beneish M-Score falls into.

POINT Biopharma Global Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of POINT Biopharma Global for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Sep23) TTM:

Last Year (Sep22) TTM:

Total Receivables was $9.4 Mil.
Revenue was 2.79 + 4.866 + 9.457 + 226.58 = $243.7 Mil.
Gross Profit was 2.79 + 4.866 + 9.457 + 226.58 = $243.7 Mil.
Total Current Assets was $353.2 Mil.
Total Assets was $477.7 Mil.
Property, Plant and Equipment(Net PPE) was $59.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.6 Mil.
Selling, General, & Admin. Expense(SGA) was $22.9 Mil.
Total Current Liabilities was $38.7 Mil.
Long-Term Debt & Capital Lease Obligation was $8.7 Mil.
Net Income was -24.774 + -25.411 + -16.531 + 163.267 = $96.6 Mil.
Non Operating Income was 5.723 + 5.167 + 5.694 + -1.724 = $14.9 Mil.
Cash Flow from Operations was -28.132 + -74.336 + -22.391 + 236.916 = $112.1 Mil.

Total Receivables was $0.2 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.0 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.0 Mil.
Total Current Assets was $296.2 Mil.
Total Assets was $325.7 Mil.
Property, Plant and Equipment(Net PPE) was $29.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.0 Mil.
Selling, General, & Admin. Expense(SGA) was $16.3 Mil.
Total Current Liabilities was $16.6 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(9.388 / 243.693)	/	(0.17 / 0)
	=	0.038524	/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(243.693 / 243.693)
	=		/	1
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (353.247 + 59.548) / 477.704)	/	(1 - (296.231 + 29.457) / 325.688)
	=	0.135877	/	0
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	243.693	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.981 / (0.981 + 29.457))	/	(2.601 / (2.601 + 59.548))
	=	0.032229	/	0.041851
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(22.883 / 243.693)	/	(16.294 / 0)
	=	0.093901	/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((8.736 + 38.666) / 477.704)	/	((0 + 16.608) / 325.688)
	=	0.099229	/	0.050994
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(96.551 - 14.86	-	112.057)	/	477.704
	=	-0.063567

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

POINT Biopharma Global Beneish M-Score Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

POINT Biopharma Global (POINT Biopharma Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

4850 West 78th Street, Indianapolis, IN, USA, 46268

Website

https://www.pointbiopharma.com

POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.

Executives

Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell	director	C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann	director, officer: Chief Executive Officer	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner	director	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472